GLP-1 medication
The program connects self-pay patients with clinicians to access GLP-1s, including Wegovy, starting at $149 per month, with no subscription fee.
The pharma giant alleges that Hims & Hers is infringing its patents and misleading consumers by selling unsafe, unapproved compounded versions of its semaglutide drugs.
Ash will provide at-home biomarker testing to Noom users to provide insights into key health markers linked to chronic disease risk and aging.
The alliance brings both companies' offerings under a single operating platform.